Breaking News Instant updates and real-time market news.

ACIW

ACI Worldwide

$31.93

-0.11 (-0.34%)

, APEN

Apollo Endosurgery

$3.68

0.19 (5.44%)

04:55
05/29/19
05/29
04:55
05/29/19
04:55

Craig Hallum to hold a conference

16th Annual Institutional Investor Conference will be held in Minneapolis, MN on May 28-29.

ACIW

ACI Worldwide

$31.93

-0.11 (-0.34%)

APEN

Apollo Endosurgery

$3.68

0.19 (5.44%)

CDNA

CareDx

$31.81

0.21 (0.66%)

DMAC

DiaMedica Therapeutics

$2.95

(0.00%)

DGII

Digi International

$11.78

0.03 (0.26%)

CY

Cypress Semiconductor

$15.39

-0.08 (-0.52%)

ENTG

Entegris

$34.31

-0.58 (-1.66%)

HIVE

Aerohive

$3.37

-0.025 (-0.74%)

HIIQ

Health Insurance Innovations

$22.98

-1.87 (-7.53%)

LASR

nLight

$19.51

-0.15 (-0.76%)

LAD

Lithia Motors

$114.39

-1.88 (-1.62%)

KN

Knowles

$15.90

-0.195 (-1.21%)

MGPI

MGP Ingredients

$63.21

-1.09 (-1.70%)

MODN

Model N

$18.46

0.365 (2.02%)

PDFS

PDF Solutions

$12.07

-0.02 (-0.17%)

RUBI

Rubicon Project

$5.79

-0.005 (-0.09%)

TEUM

Pareteum

$4.74

0.02 (0.42%)

SYNA

Synaptics

$27.14

-0.59 (-2.13%)

SWKS

Skyworks

$68.01

-1.5 (-2.16%)

UCTT

Ultra Clean

$12.58

-0.02 (-0.16%)

OMCL

Omnicell

$81.13

-0.03 (-0.04%)

STM

STMicroelectronics

$15.10

-0.14 (-0.92%)

TTGT

TechTarget

$20.24

0.38 (1.91%)

WTW

Symbol now WW

$0.00

(0.00%)

  • 29

    May

  • 29

    May

  • 29

    May

  • 30

    May

  • 30

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 04

    Jun

  • 05

    Jun

  • 06

    Jun

  • 06

    Jun

  • 07

    Jun

  • 11

    Jun

  • 11

    Jun

  • 11

    Jun

  • 12

    Jun

  • 12

    Jun

  • 17

    Jun

  • 18

    Jun

  • 18

    Jun

  • 19

    Jun

  • 24

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 13

    Nov

ACIW ACI Worldwide
$31.93

-0.11 (-0.34%)

01/03/19
SPHN
01/03/19
DOWNGRADE
Target $30
SPHN
Equal Weight
ACI Worldwide downgraded to Equal Weight from Overweight at Stephens
Stephens analyst Brett Huff downgraded ACI Worldwide to Equal Weight from Overweight as he is worried that OnDemand won't achieve the high single-digit growth the market expects and sees opportunities for competitors to take some share during the transitions of clients from the company's old to its new systems. Huff lowered his price target on ACI Worldwide shares to $30 from $33 as he also updated his estimates.
03/08/19
SPHN
03/08/19
UPGRADE
Target $38
SPHN
Overweight
ACI Worldwide upgraded to Overweight from Equal Weight at Stephens
Stephens analyst Brett Huff upgraded ACI Worldwide (ACIW) to Overweight and raised his price target for the shares to $38 from $30. The analyst views the company's acquisition of Western Union's (WU) Speedpay as a "great deal." Shares of ACI only moved 3% despite its guided double-digit accretion, Huff tells investors in a research note. He believes the deal should lead to higher estimates and sees a low likelihood of another offer coming in for Speedpay.
05/24/19
SPHN
05/24/19
NO CHANGE
SPHN
Global Payments, TSYS tie-up would likely be highly accretive, says Stephens
Stephens analyst Brett Huff noted that Bloomberg reports that Global Payments (GPN) and TSYS (TSS) have held talks about a potential merger, joint venture and/or partnerships. While he has previously thought that Global Payments had the luxury of "waiting and seeing" if combining consumer funding account with a merchant POS experience, such as the Fiserv (FISV)-First Data (FDC) and FIS (FIS)-Worldpay (WP) deals will do, would yield enough strategic value, he suspects a sooner deal might be driven by the companies' desire to not just achieve larger scale but also achieve that scale with high-quality assets. Huff said he thinks any deal would likely be highly accretive given overlaps and both companies' track record for realizing cost synergies and he also sees limited antitrust concern. Huff also thinks a Global Payments-TSYS combination would increase the chances that assets such as ACI Worldwide (ACIW), Bottomline Technologies (EPAY), Jack Henry (JKHY), USA Technologies (USAT) and Q2 Holdings (QTWO) would likely be bought.
APEN Apollo Endosurgery
$3.68

0.19 (5.44%)

12/18/18
CHLM
12/18/18
NO CHANGE
CHLM
Craig-Hallum says Apollo's divestiture makes it more attractive takever target
Craig-Hallum analyst Matt Hewitt reiterated a Buy rating and $11 price target on Apollo Endosurgery after the company announced the divestiture of its Surgical segment to ReShape Lifesciences, which brings in $10M immediately along with $7M more in the coming years. Hewitt views the sale as a positive, as the segment had been set to decline by 33% in FY18. The analyst added that now that Apollo is strictly an endo-bariatric company, he views it as "significantly more attractive to potential acquirers."
03/18/19
PIPR
03/18/19
NO CHANGE
Target $5.5
PIPR
Overweight
Piper says Apollo's OverStitch growth more important than balloon sales declines
Piper Jaffray analyst JP McKim noted that Apollo Endosurgery reported Q4 sales and gave 2019 guidance that were both relatively in-line with estimates, but he believes the fact that OverStitch sales outperformed expectations is more important than the decline in balloon sales. While the early feedback from the alpha launch was positive, McKim believes Apollo will need to show execution on SX sales before seeing its multiple expand. He keeps an Overweight rating and $5.50 price target on Apollo Endosurgery.
01/02/19
NORL
01/02/19
UPGRADE
Target $3
NORL
Market Perform
Apollo Endosurgery upgraded to Market Perform from Underperform at Northland
Northland analyst Suraj Kalia upgraded Apollo Endosurgery to Market Perform and maintained a $3 price target citing valuation.
12/18/18
PIPR
12/18/18
NO CHANGE
Target $5.5
PIPR
Overweight
Apollo Endosurgery target lowered to $5.50 from $7 at Piper Jaffray
Piper Jaffray analyst JP McKim says this morning's sale of its surgical business to ReShape provides Apollo Endosurgery management a "great" opportunity to right-size the company and focus on higher growth, unique assets such as OverStitch SX. Despite the favorable view of the deal, the analyst lowered his price target for the shares to $5.50 from $7.00 based on a reduced 2019 revenue estimate and a slightly reduced target multiple. Management will need to show execution on SX sales before getting the multiple expansion benefit, McKim tells investors in a research note. He keeps an Overweight rating on Apollo Endosurgery.
CDNA CareDx
$31.81

0.21 (0.66%)

05/09/19
PIPR
05/09/19
NO CHANGE
Target $50
PIPR
Overweight
CareDx price target raised to $50 from $42 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for CareDx to $50 from $42 following the company's better than expected Q1 results and increased outlook. CareDx has widened its "competitive moat" in transplant medicine with KidneyCare, Quirk tells investors in a research note. The stock remains his top small cap idea with an Overweight rating.
03/07/19
PIPR
03/07/19
NO CHANGE
Target $42
PIPR
CareDx remains a top small cap idea at Piper Jaffray
Piper Jaffray analyst William Quirk says CareDx's Q4 results were driven by strong AlloSure performance and enrollment expansion in the K-OAR study. The analyst views the company's 2019 revenue guidance as conservative and believes its competitive moat in transplant medicine continues to widen. The stock remains his top small cap idea and Quirk reiterates an Overweight rating on CareDx with a $42 price target.
05/09/19
HCWC
05/09/19
UPGRADE
Target $43
HCWC
Buy
CareDx upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju upgraded CareDx to Buy from Neutral and raised his price target for the shares to $43 from $30. The company in Q1 posted positive EBITDA for the third consecutive quarter, Selvaraju tells investors in a research note. The analyst believes CareDx could achieve positive EBITDA sustainably going forward.
03/28/19
RAJA
03/28/19
NO CHANGE
RAJA
Strong Buy
CareDx lawsuit against Natera 'not unexpected,' says Raymond James
Raymond James analyst John Hsu notes that CareDx (CDNA) announced the filing of a patent infringement lawsuit against Natera (NTRA), which was "not unexpected." The analyst sees the lawsuit as consistent with management seeking to protect the company's intellectual property, and notes that the court process could take up to three years. While this lawsuit is a "logical course of action," Hsu believes CareDx remains focused on building its moat in kidney transplant, with sales force investments and a focus on integration with hospital electronic medical records. Overall, the analyst still views 2019's main focus on other activities to strengthen a "significant head start on the back of a best-in-class product launch in 2018." He reiterates a Strong Buy rating on CareDx shares.
DMAC DiaMedica Therapeutics
$2.95

(0.00%)

04/30/19
DOTC
04/30/19
INITIATION
Target $8
DOTC
Buy
DiaMedica Therapeutics initiated with a Buy at Dougherty
Dougherty analyst Kyle Bauser initiated DiaMedica Therapeutics with a Buy rating and $8 price target, citing what he calls a "large body of clinical evidence" supporting the benefit of KLK1 to treat Chronic Kidney Disease and acute ischemic stroke. He notes that data readouts are due later this year from company's synthetic version of KLK1.
01/03/19
CHLM
01/03/19
INITIATION
Target $9
CHLM
Buy
DiaMedica Therapeutics initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Alexander Nowak started DiaMedica Therapeutics with a Buy rating and a $9 price target. The analyst believes its unique stroke and kidney treatment validated in China sets up DiaMedica as a high reward opportunity, while positive Phase 2 results could move the stock above his price target.
DGII Digi International
$11.78

0.03 (0.26%)

09/27/18
LSCM
09/27/18
NO CHANGE
Target $16
LSCM
Buy
Digi International shares can 'work meaningfully higher,' says Lake Street
Lake Street analyst Jaeson Schmidt believes shares of Digi International "can work meaningfully higher from current levels" as investors gain confidence in the ramp of the company's Internet of Things Solutions business and start to better appreciate the potential earnings leverage in the model. After visiting Digi's headquarters, the analyst feels confident that the company "remains on a path of sustained, solid top line growth and improving profitability." He reiterates a Buy rating on Digi International with a $16 price target.
07/27/18
LSCM
07/27/18
NO CHANGE
Target $16
LSCM
Buy
Digi International price target raised to $16 from $14 at Lake Street
Lake Street analyst Jaeson Schmidt raised his price target for Digi International to $16 saying the company reported a "solid" quarter and revenue outlook with Internet of Things continuing to ramp. The analyst reiterates a Buy rating on the shares.
06/20/18
ADAM
06/20/18
NO CHANGE
Target $18
ADAM
Buy
Digi International price target raised to $18 from $15 at Canaccord
Canaccord analyst T. Michael Walkley raised his price target on Digi International to $18 from $15 following meetings with management. The analyst said the meeting focused on the cold chain monitoring market opportunity and he believes Digi has the team and solution sets to emerge as a leader in the fragmented market. Walkley reiterated his Buy rating on Digi International shares.
07/05/18
FANA
07/05/18
NO CHANGE
Target $16
FANA
Overweight
Digi International target raised to $16 after CFO call at First Analysis
First Analysis analyst David Gearhart raised his price target for Digi International to $16 from $15 following a call with new CFO Gokul Hemmady. The analyst came away with greater confidence that management will execute on its end-to-end solutions strategy and be able to return the core hardware business to "sustained growth while maintaining solid profitability, driving above-market share returns." Gearhart reiterates an Overweight rating on Digi shares.
CY Cypress Semiconductor
$15.39

-0.08 (-0.52%)

03/14/19
MKMP
03/14/19
NO CHANGE
Target $18
MKMP
Buy
Cypress Semiconductor price target raised to $18 from $16 at MKM Partners
MKM Partners analyst Ruben Roy raised his price target on Cypress Semi to $18 and kept his Buy rating after its Analyst Day presentation yesterday. The analyst says the company's focus on Internet of Things and Automotive markets position it for above-market growth rates, with the management presentation offering a "good look into various examples and company specific differentiation" that should support its forecasts. Roy adds that the company's increase in longer-term gross margin forecasts and attractive valuation warrant a price target increase.
03/28/19
MSCO
03/28/19
DOWNGRADE
Target $24.5
MSCO
Equal Weight
Quantenna Communications downgraded to Equal Weight at Morgan Stanley
Morgan Stanley analyst Craig Hettenbach downgraded Quantenna Communications (QTNA) to Equal Weight from Overweight and raised his price target on the stock to $24.50 from $18.00 to reflect the company's agreement to be acquired by ON Semiconductor (ON). For ON, Hettenbach estimates a stock buyback would be "meaningfully more accretive over the intermediate term," stating that the company said they expect the deal to be around 5c accretive to EPS but using the same amount of cash to buy back stock at an average price of $22 could add 20c to 2020 EPS. The analyst, who sees other competitors - such as Cypress (CY), Microchip (MCHP) and Texas Instruments (TXN) - being "much better positioned" in low power WiFi, keeps an Underweight rating on ON Semiconductor shares.
03/28/19
MSCO
03/28/19
NO CHANGE
MSCO
Infineon warning a 'reality check' for semiconductor group, says Morgan Stanley
Morgan Stanley analyst Craig Hettenbach noted that Infineon cut its FY19 revenue guidance by around 3.5% yesterday, citing elevated inventory in China autos and distribution broadly. Hettenbach calls the negative pre-announcement "an important reality check for semis" that calls into question recently building optimism for a second half rebound. Hettenbach maintains a Cautious view on Semis as a group and lists Sensata (ST), NXP Semiconductors (NXPI), TE Connectivity (TEL), Cypress Semiconductor (CY) and ON Semiconductor (ON) as stocks he covers that have meaningful exposure to autos.
04/12/19
NEED
04/12/19
NO CHANGE
Target $20
NEED
Buy
Cypress Semiconductor price target raised to $20 from $16 at Needham
Needham analyst Rajvindra Gill raised his price target on Cypress Semiconductor to $20 and kept his Buy rating to reflect his "stronger conviction" for the company's margin profile and his favorable sales mix outlook. In spite of the 25% year-to-date rise, the analyst points to the stock trading near a multi-year price-to-earnings lows, along with the company's "defensible technological barriers in Wi-Fi/Bluetooth Low Energy, high-density NOR memory, and PSoC microcontroller." Gill further believes that Cypress Semi is well positioned in the Internet of Things, auto, and industrial industries experiencing secular growth.
ENTG Entegris
$34.31

-0.58 (-1.66%)

05/10/19
SBSH
05/10/19
DOWNGRADE
SBSH
Neutral
Entegris downgraded to Neutral from Buy at Citi
Citi analyst Atif Malik downgraded Entegris to Neutral from Buy.
05/10/19
SBSH
05/10/19
DOWNGRADE
SBSH
Neutral
Citi downgrades Entegris and Universal Display to Neutral from Buy
Citi analyst Atif Malik downgraded both Entegris (ENTG) and Universal Display (OLED) to Neutral from Buy. The analyst expects consumable stocks tied to overall wafer or display starts to "slow down" in the second half of 2019. His top picks in Semiconductor Capital Equipment remain Lam Research (LRCX) and Applied Materials (AMAT), which he notes have high exposure to the memory end market. Assuming no recession, Malik believes the group bottomed in Q1 as year-over-year memory supply growth peaked.
05/10/19
05/10/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Hudbay Minerals (HBM) downgraded to Market Perform from Outperform at BMO Capital wwith analyst Jackie Przybylowski saying the company is entering a "naturally relatively slow period" in its news flow. 2. Nevro (NVRO) downgraded to Hold from Buy at Canaccord with analyst Jason Mills stating that while he expected Q1 would be "ugly," results were "a little worse" than he expected. 3. Interxion (INXN) downgraded to Perform from Outperform at Oppenheimer with analyst Tim Horan citing valuation. 4. Entegris (ENTG) downgraded to Neutral from Buy at Citi with analyst Atif Malik saying he expects consumable stocks tied to overall wafer or display starts to "slow down" in the second half of 2019. 5. SharpSpring (SHSP) downgraded to Hold from Buy at Craig-Hallum with analyst Mike Malouf stating the company is effectively competing against market leaders and gaining share, but that its increasing marketing and R&D spending will push out profitability. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/25/19
04/25/19
NO CHANGE

Entegris reports Q1 non-GAAP EPS 50c, consensus 47c
Reports Q1 revenue $391.0M, consensus $400.43M.
HIVE Aerohive
$3.37

-0.025 (-0.74%)

HIIQ Health Insurance Innovations
$22.98

-1.87 (-7.53%)

05/24/19
RILY
05/24/19
NO CHANGE
Target $45
RILY
Buy
Court filing looks favorable for Health Insurance Innovations, says B. Riley FBR
The U.S. Court for the Southern District of Florida yesterday filed a ruling regarding the ongoing legal matter between the Federal Trade Commission and Simple Health, B. Riley FBR analyst Randy Binner tells investors in a research note. The analyst's read of the filing is that Health Insurance Innovations is in agreement with, and will execute the process of, the notification of Simple Health clients that they may have been mis-sold health insurance policies by Simple Health. Binner, who admits to not knowing if Health Insurance Innovations will be reimbursed for the cost of these notifications, expects this process to have a marginal financial impact on the company. The ruling also notes that Health Insurance does not admit culpability, nor was found culpable, for the underlying conduct of Simple Health, the analyst adds. He believes the resolution of uncertainty around the FTC matter should be positive for Health Insurance shares. He maintains a Buy rating on Health Insurance Innovations with a $45 price target.
05/08/19
CANT
05/08/19
NO CHANGE
Target $75
CANT
Overweight
Cantor views new Health Insurance disclosure on Simple Health positively
Health Insurance Innovations last night in its quarterly filing updated its disclosure regarding the ongoing dispute between the FTC and one of its former distributors, Simple Health, Cantor Fitzgerald analyst Steven Halper told investors earlier in a research note. The disclosure indicates that Health Insurance is not a defendant or party in the case and has been in regular dialogue with the FTC, says the analyst. He views the disclosure positively and reiterates his view that concerns regarding the company's exposure to FTC lawsuit against Simple Health are "entirely overblown." Shares of Health Insurance Innovations are up 8c to $22.02 in morning trading.
05/07/19
LSCM
05/07/19
NO CHANGE
Target $50
LSCM
Buy
Health Insurance Innovations price target lowered to $50 from $80 at Lake Street
Lake Street analyst Mark Argento lowered his price target for Health Insurance Innovations to $50 from $80 following the company's Q1 results while keeping a Buy rating on the shares. Strong policy duration growth has been offset by lower new policy adds and higher duration and expenses in the last two quarters, which is likely to persist in Q2 given management's updated quarterly guidance, Argento tells investors in a research note. The analyst points out that Health Insurance's fiscal 2019 guidance is now increasingly back-end loaded.
05/02/19
RAJA
05/02/19
NO CHANGE
Target $50
RAJA
Outperform
Health Insurance Innovations stock looks 'broken,' says Raymond James
Raymond James analyst C. Gregory Peters keeps an Outperform rating on Health Insurance Innovations shares, but said he fears the stock "appears to be broken" and could see additional weakness as broker-dealers have to short more shares to keep their books neutral if the stock continues to slide. While he does not believe that legislation introduced in the House of Representatives to prevent the enforcement of a recent regulation aimed at increasing the number of people with short-term limited duration insurance will see action in the Senate, Peters acknowledges the overhang that the bill has been on Health Insurance Innovations shares.
LASR nLight
$19.51

-0.15 (-0.76%)

05/16/19
BNCH
05/16/19
NO CHANGE
BNCH
II-VI, Lumentum may be hurt by Huawei news, says Benchmark
After the U.S. Commerce Department added Huawei Technologies and 70 affiliates to its "Entity List," which bans the Chinese company from acquiring components and technology from U.S. companies without government approval, Benchmark analyst Mark Miller noted that prior restrictions negatively impacted II-VI (IIVI), which counts Huawei among its customers. He also believes Lumentum (LITE) may be unfavorably impacted as Huawei represents about 15% of its revenue. Huawei has contributed about 13% of Micron's (MU) sales in the last two quarters and shares of Western Digital (WDC) often trade in a similar manner to Micron, added Miller. Others that he sees potentially being negatively impacted by the Huawei news include IPG Photonics (IPGP), Coherent (COHR), nLight (LASR) and Veeco (VECO).
05/09/19
BNCH
05/09/19
UPGRADE
BNCH
Hold
nLight upgraded to Hold from Sell at Benchmark
Benchmark analyst Mark Miller upgraded nLight to Hold from Sell following last night's Q1 results. The analyst says that while the shares are pricey, he expects the company to report sequential growth.
02/27/19
NRCS
02/27/19
NO CHANGE
NRCS
January Laser Industry survey shows continued mixed outlook, says Northcoast
Northcoast analyst Tom Hayes says his January Laser Industry survey showed some deterioration on a sequential basis as domestic respondents were less optimistic for Q1 and the international market continues to be choppy with limited visibility. While most respondents in his survey continue to expect growth in Q1 and 2019, the analyst notes that a combination of geopolitical headwinds, palpably weaker outlook and lack of clarity in the space gives him pause. Consequently, he reiterates a Neutral rating on nLight (LASR), IPG Photonics (IPGP) and Coherent (COHR).
05/09/19
BNCH
05/09/19
UPGRADE
BNCH
Hold
nLight upgraded to Hold on sequential growth forecast at Benchmark
As previously reported, Benchmark analyst Mark Miller upgraded nLight to Hold from Sell following last night's Q1 results. Modest annual sales growth is expected in 2019 and he projects 15% year-over-year top line growth in 2020, Miller tells investors in a corrected research note.
LAD Lithia Motors
$114.39

-1.88 (-1.62%)

05/06/19
MSCO
05/06/19
UPGRADE
Target $94
MSCO
Overweight
Morgan Stanley more positive on auto dealers, upgrades Group 1 to Overweight
As previously reported, Morgan Stanley analyst Armintas Sinkevicius upgraded Group 1 Automotive (GPI) to Overweight from Equal Weight as he turns positive on the traditional auto dealer group and named it his top pick among the traditional dealers. Sinkevicius sees the potential for an elongated auto cycle following changes to the Fed policy, he noted, adding that he is also drawn to the defensiveness of the dealer model and investor positioning. The analyst, who noted that his estimates are above consensus for all of the traditional dealers in Q2 and for 2019, raised his price target on Group 1 shares to $94 from $67, raised his target on Asbury Automotive (ABG) to $87 from $85, upped his target on AutoNation (AN) to $36 from $27, raised his target on Lithia Motors (LAD) to $128 from $117, increased his target on Sonic Automotive (SAH) to $18 from $10 and keeps a $56 price target on Penske Automotive (PAG).
04/25/19
CHLM
04/25/19
NO CHANGE
Target $125
CHLM
Buy
Lithia Motors price target raised to $125 from $103 at Craig-Hallum
Craig-Hallum analyst Steve Dyer raised his price target for Lithia Motors to $125 from $103 given profit growth and margin expansion amid industry slowdown, which highlights attractiveness of its business model. The analyst reiterates a Buy rating on the shares.
04/25/19
SPHN
04/25/19
UPGRADE
Target $132
SPHN
Overweight
Stephens upgrades Lithia Motors after third straight 'solid' quarter
Stephens analyst Rick Nelson upgraded Lithia Motors to Overweight from Equal Weight and raised his price target for the shares to $132 from $106. The company has posted three consecutive quarters of solid results, including Q1 earnings per share up 17%, Nelson tells investors in a research note. Operational improvements in recently acquired stores are gaining traction and provide a "multi-year tailwind as store operations ramp to full potential," adds the analyst. He believes Lithia is demonstrating it can grow in declining auto environment.
04/26/19
BOFA
04/26/19
DOWNGRADE
BOFA
Neutral
Lithia Motors downgraded to Neutral on valuation at BofA/Merrill
BofA/Merrill analyst John Murphy downgraded Lithia Motors to Neutral from Buy citing valuation following the recent share strength since the Q1 report. Murphy raised Lithia's price target to $115 from $102 to reflect improved growth in the Parts & Service and Used vehicle segments.
KN Knowles
$15.90

-0.195 (-1.21%)

02/08/19
LSCM
02/08/19
DOWNGRADE
Target $17
LSCM
Hold
Knowles downgraded to Hold from Buy at Lake Street
Lake Street analyst Jaeson Schmidt downgraded Knowles to Hold with an unchanged price target of $17. While the company can be the dominant player in the market and think its share at Apple is set to remain stable in the future, increasing uncertainty on the health of the global smartphone market could create headwinds to the stock's multiple, Schmidt tells investors in a research note. He sees "limited room for meaningful multiple expansion" following Knowles' Q4 results.
04/02/19
JPMS
04/02/19
NO CHANGE
Target $15
JPMS
Underweight
Knowles shares fully valued at current levels, says JPMorgan
JPMorgan analyst Bill Peterson believes the losses for Knowles' Intelligent Audio, as described in the letter by two activists, appear to be overstated. Further, the losses are on track to significantly narrow this year with the potential for Intelligent Audio to achieve operating breakeven next year, Peterson tells investors in a research note. Regarding Precision Devices, the analyst agrees the segment has negligible synergies with the core Audio. However, should Knowles divest the segment, its earnings power would likely be reduced by 20%-25% in the near term, he adds. Peterson finds shares of Knowles fully valued and keeps an Underweight rating on the name with a $15 price target.
03/04/19
SUSQ
03/04/19
NO CHANGE
SUSQ
Positive
Cirrus Logic, Qualcomm winners in S10 teardown, Knowles loser, says Susquehanna
Susquehanna analyst Christopher Rolland disassembled the Korean version of Samsung's (SSNLF) Galaxy S10 and he found Cirrus Logic (CRUS) won the new amplifier sockets as well as maintaining their codec in the Exynos version. The analyst found Qualcomm (QCOM) has won the under-glass fingerprint sensor, apparently for all designs, not just those using a Qualcomm AP. He said this is a new source of revenue for Qualcomm. He noted the big loser was Knowles (KN) because traditionally Samsung used microphone MEMS from Knowles but in the GS10 not one but two microphones are supplied by GoerTek.
02/08/19
02/08/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Fiat Chrysler (FCAU) downgraded to Equal Weight from Overweight at Barclays with analyst Brian Johnson saying he is surprised by the "NAFTA earnings plateau" and views the company's 2020 targets as aggressive. 2. Kellogg (K) downgraded to Hold from Buy at Pivotal Research with analyst Timothy Ramey saying the company's adjusted earnings in Q4 disappointed and it "celebrated 0% organic top line growth for the year citing the heavy lift of reversing the negative trajectory." 3. NXP Semiconductors (NXPI) downgraded to Neutral from Buy at Mizuho with analyst Vijay Rakesh saying with the stock up 40% from the December lows, high China auto inventory and Europe's Worldwide Harmonised Light Vehicle Test Procedure "could present challenges and limit upside." 4. Synaptics (SYNA) downgraded to Neutral from Overweight at JPMorgan with analyst Paul Coster saying the company reported "solid" fiscal Q2 results, driven by further improvement in gross margins, but issued "slightly disappointing" Q3 guidance owing to soft demand in the handset market. 5. Knowles (KN) downgraded to Hold from Buy at Lake Street with analyst Jaeson Schmidt saying while the company can be the dominant player in the market and think its share at Apple (AAPL) is set to remain stable in the future, increasing uncertainty on the health of the global smartphone market could create headwinds to the stock's multiple. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MGPI MGP Ingredients
$63.21

-1.09 (-1.70%)

12/13/18
RHCO
12/13/18
NO CHANGE
Target $90
RHCO
Buy
MGP Ingredients price target lowered to $90 from $100 at SunTrust
SunTrust analyst William Chappell lowered his price target on MGP Ingredients to $90 to reflect the multiple compression in the industry, modeling a 19-times multiple for its expected forward EBITDA. The analyst also keeps his Buy rating on the shares after traveling with the company management, saying that the company is positioned to monetize its aged whiskey inventory potential as the first batch of its distilled product comes of age in 2019. Chappell further states that both aged and unaged whiskey sales will accelerate in 2019 and "substantially boost" MGP Ingredients' profit base.
MODN Model N
$18.46

0.365 (2.02%)

11/07/18
NEED
11/07/18
DOWNGRADE
NEED
Hold
Model N downgraded to Hold from Buy at Needham
11/07/18
NEED
11/07/18
DOWNGRADE
NEED
Hold
Model N downgraded to Hold from Buy at Needham
As noted earlier, Needham analyst Ryan MacDonald downgraded Model N to Hold from Buy, saying its "elongated transition of existing customers to SaaS" is having a negative impact on its financial outlook. The analyst notes that he initially estimated the company's recurring revenue growth to reach as high as 15% based on its Life Science customer transitions and net new customer wins, but now sees that growth rate in the mid-to-high single digit rate amid the challenges of ramping deal structure adoption and headwind from the adoption of ASC606. As such, MacDonald believes that Model N shares are "accurately valued at current levels."
11/07/18
CHLM
11/07/18
NO CHANGE
Target $20
CHLM
Buy
Model N price target lowered to $20 from $25 at Craig-Hallum
Craig-Hallum analyst Chad Bennett lowered his price target for Model N to $20 from $25 saying that while Q4 results beat expectations, FY19 guidance continues to be impacted by SaaS transition and ASC606. Nonetheless, the analyst continues to believe growth will accelerate in FY20. He reiterates a Buy rating on the shares.
02/19/19
NATL
02/19/19
INITIATION
Target $23
NATL
Buy
Model N initiated with a Buy at National Securities
National Securities initiated Model N with a Buy and $23 price target.
PDFS PDF Solutions
$12.07

-0.02 (-0.17%)

08/29/18
DADA
08/29/18
NO CHANGE
Target $13
DADA
Buy
PDF Solutions price target lowered to $13 from $18 at DA Davidson
DA Davidson analyst Thomas Diffely lowered his price target on PDF Solutions to $13 after yesterday's decision by Global Foundries, to put its 7nm program on hold and to drop its plans to pursue the next generation advanced nodes. The analyst states that while PDF Solutions' exposure to Global Foundries is declining from 40% to 30%, it is still its largest customer, and the announcement has a bearing on its already drifting core yield enhancement business. Diffely keeps his Buy rating on the shares however given the potential upside in the stock price after its 13% slide yesterday.
RUBI Rubicon Project
$5.79

-0.005 (-0.09%)

10/12/18
CHLM
10/12/18
NO CHANGE
CHLM
Buy
Rubicon Project lawsuit settlement removes overhang, says Craig-Hallum
Rubicon Project has reached an agreement to settle a lawsuit with The Guardian, Craig-Hallum analyst Jason Kreyer tells investors in a research note. Kreyer believes the settlement removes an overhang on the stock, and notes that the financial terms of the settlement are immaterial. The analyst continues to see an improving fundamental opportunity for Rubicon Project and maintains a Buy rating.
06/26/18
CHLM
06/26/18
NO CHANGE
Target $4
CHLM
Buy
Rubicon Project to benefit from AT&T acquisition of AppNexus, says Craig-Hallum
Craig-Hallum analyst Jason Kreyer notes that AT&T (T) announced the acquisition of AppNexus, a deal rumored to be valued at $1.6B. The analyst sees this deal having a ripple effect through the ad tech landscape, particularly as it relates to the publisher's end of the spectrum. In his view, Rubicon Project (RUBI) stands to benefit substantially by the removal of an aggressive competitor, with thousands of publishers and hundreds of millions of advertising spend likely searching for a new home. Further, Kreyer now sees the integration of AppNexus under the AT&T umbrella as the number one growth catalyst for Rubicon over the next 12-18 months as a substantial volume of ad impressions likely search for a new home. He reiterates a Buy rating and $4 price target on Rubicon's shares.
04/17/19
RILY
04/17/19
INITIATION
Target $9
RILY
Buy
Rubicon Project initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Lee Krowl started Rubicon Project with a Buy rating and $9 price target. The analyst sees the company as fundamentally well positioned following a multiyear restructuring and industry "shakeout."
04/02/19
CHLM
04/02/19
NO CHANGE
Target $8
CHLM
Buy
Chrome changes overblown, buying opportunity for Rubicon, says Craig-Hallum
Craig-Hallum analyst Jason Kreyer believes the recent pullback in Rubicon Project (RUBI) shares creates a buying opportunity. Shares were down nearly 10% last week following rumors that Google (GOOG) could make privacy changes to its Chrome browser, he notes. The analyst does not anticipate this creating any fundamental headwinds for Rubicon Project and believes management's focus on releasing a suite of tools for publishers positions the company for further competitive gains. He reiterates a Buy rating and $8 price target on Rubicon's shares.
TEUM Pareteum
$4.74

0.02 (0.42%)

04/25/19
OPCO
04/25/19
INITIATION
Target $7
OPCO
Outperform
Pareteum initiated with an Outperform at Oppenheimer
Oppenheimer analyst Timothy Horan started Pareteum with an Outperform rating and $7 price target.
05/08/19
LSCM
05/08/19
NO CHANGE
Target $6.5
LSCM
Buy
Pareteum target raised to $6.50 after Q1 beat at Lake Street
Lake Street analyst Eric Martinuzzi raised his price target for Pareteum to $6.50 from $6.00 citing the company's Q1 beat and guidance boost. Pareteum is getting better at turning away custom contracts and selling what can be deployed immediately, Martinuzzi tells investors in a research note. He believes investors were anticipating a good Q1, but that Pareteum did better than expected. The analyst keeps a Buy rating on the shares.
04/26/19
OPCO
04/26/19
INITIATION
Target $7
OPCO
Outperform
Oppenheimer sees above 30% revenue growth for Pareteum, starts at Outperform
Oppenheimer analyst Timothy Horan last night initiated coverage of Pareteum with an Outperform rating and $7 price target. Pareteum has a software solution for enabling mobile virtual network operators, Internet of Things and applications on one network/cloud, Horan tells investors in a research note. The analyst believes the company can grow revenues above 30% for the next five years and ultimately double its 15% EBITDA margins. There are high barriers to entry to its integrated service, and most competitors have major channel conflicts, Horan contends. Further, Pareteum's backlog has seen "very strong growth" in the last few quarters, providing visibility on revenue growth, he adds.
02/19/19
NORL
02/19/19
NO CHANGE
Target $7.5
NORL
Outperform
Pareteum 'undervalued' following January wins, says Northland
Northland analyst Michael Latimore notes that Pareteum announced on Friday 12 wins in the month of January. The analyst likes that the company is winning more U.S.-based customers, and argues that the wins and associated increase in backlog give him more confidence in his estimates. Overall, Latimore believes Pareteum is undervalued, trading at only 3.76 times his FY19 revenue estimates and 2.93 times FY20. He reiterates an Outperform rating and $7.50 price target on the shares.
SYNA Synaptics
$27.14

-0.59 (-2.13%)

05/10/19
CHLM
05/10/19
NO CHANGE
Target $39
CHLM
Buy
Synaptics price target lowered to $39 from $47 at Craig-Hallum
Craig-Hallum analyst Anthony Stoss lowered his price target for Synaptics to $39 from $47 and maintained a Buy rating after the company guided well below Street estimates for the June quarter, saying that with Synaptics trading down ~20% since his cautious preview, the stock is cheap enough to be interesting to investors at just 9.6x his reset FY20 estimates. Stoss reiterated his Buy rating, adding that Synaptics had some encouraging commentary on its conference call highlighting several new design wins for OLED DDICs in smartphones and a new USB-C solution shipping into what the analyst believes is Samsung's note headphones that ship in the box.
05/10/19
BMOC
05/10/19
NO CHANGE
Target $29
BMOC
Market Perform
Synaptics price target lowered to $29 from $35 at BMO Capital
BMO Capital analyst Ambrish Srivastava lowered his price target on Synaptics to $29 after its mixed Q3 results showed a beat on earnings thanks to higher gross margins but a miss on revenue. The analyst cites the company's 25% and 28% sequential declines in Mobile products and IoT products respectively, even though its PC product segment was up 4%. Srivastava also keeps his Market Perform rating and sees Synaptics stock as reasonably valued at current levels.
03/18/19
JPMS
03/18/19
NO CHANGE
Target $45
JPMS
Neutral
Synaptics price target lowered to $45 from $50 at JPMorgan
JPMorgan analyst Paul Coster lowered his price target for Synaptics to $45 from $50 after the company negatively preannounced Q3 results and said CEO Rich Bergman will be departing immediately. In a research note titled "Mildly Negative F3Q19 Preannouncement; CEO Resigns; Typically Not Good Things," the analyst says he expects the demand environment to remain soft for Synaptics. He keeps a Neutral rating on the shares.
03/19/19
BMOC
03/19/19
NO CHANGE
Target $35
BMOC
Market Perform
Synaptics price target lowered to $35 from $42 at BMO Capital
BMO Capital analyst Ambrish Srivastava lowered his price target on Synaptics to $35 and kept his Market Perform rating after the company's announced "immediate" CEO departure and Q3 outlook at the lower end of its earlier forecast late on Friday. The analyst also lowers his FY19 and FY20 EPS outlook to $4.23 and $3.57 from $4.52 and $4.26 respectively while noting that the shares remain "reasonably valued" at these levels in spite of Monday's 22% stock price decline.
SWKS Skyworks
$68.01

-1.5 (-2.16%)

05/21/19
ADAM
05/21/19
NO CHANGE
Target $90
ADAM
Buy
Skyworks price target lowered to $90 from $99 at Canaccord
Cannacord analyst T. Michael Walkley lowered his price target for Skyworks to $90 from $99 but maintained a Buy rating after the Commerce Department added Huawei and its affiliates to its "Entity List" prohibiting U.S.-origin technology to be supplied to Huawei without a license. Walkley lowered his estimates for Skyworks to account for the potential extended disruption, reducing both his Broad market and handset related estimates with Q3 and FY19 revenue declining from $825M to $788M and adjusted EPS from $1.50 to $1.40, reflecting the inability to ship to Huawei. While the analyst said this ban could potentially resolve as part of a broader trade deal in weeks to even months, he reduced his calendar 2019 and calendar 2020 estimates given the uncertainty and sharp decline in Skyworks' share price.
05/03/19
CHLM
05/03/19
NO CHANGE
Target $105
CHLM
Buy
Skyworks price target raised to $105 from $90 at Craig-Hallum
Craig-Hallum analyst Anthony Stoss raised his price target for Skyworks to $105 from $90 and maintained a Buy rating after the company reported results in-line with estimates as weakness in China was offset by strength in Broad Markets. Stoss tells investors in a research note that he believes Skyworks will benefit from significant content expansion in 2020 as 5G phones rollout in volume.
05/03/19
BMOC
05/03/19
NO CHANGE
Target $105
BMOC
Outperform
Skyworks price target raised to $105 from $94 at BMO Capital
BMO Capital analyst Ambrish Srivastava raised his price target on Skyworks to $105 and kept his Outperform rating after its Q2 earnings beat, saying the management was "appropriately conservative" in its conference call tone given the " inherent volatility in the smartphone market." The analyst also expects "seasonal" September demand and anticipates China performance to be incrementally better, recommending that investors take advantage of any "undue weakness" in shares.
05/16/19
MSCO
05/16/19
NO CHANGE
MSCO
Micron, Skyworks, Qorvo among chipmakers exposed to Huawei, says Morgan Stanley
Following media reports discussing a potential ban of sales from U.S. companies to Huawei, Morgan Stanley analyst Joseph Moore identified semiconductor companies with exposure to the company, including Skyworks (SWKS), Qorvo (QRVO), Broadcom (AVGO), Analog Devices (ADI), ON Semiconductor (ON), Maxim (MXIM), Texas Instruments (TXN), Xilinx (XLNX), Micron (MU) and Inphi (IPHI). In his note, Moore recalled that a similar ban on ZTE (ZTCOY) last year was ultimately removed.
UCTT Ultra Clean
$12.58

-0.02 (-0.16%)

12/21/18
NEED
12/21/18
INITIATION
Target $13
NEED
Buy
Ultra Clean initiated with a Buy at Needham
Needham analyst N. Quinn Bolton started Ultra Clean with a Buy rating and $13 price target, stating that the company is highly leveraged to the expected recovery in WFE spending in the second half of 2019. He also believes there will be reduced volatility in its business with the recent acquisition of Quantum Global, Bolton tells investors.
03/11/19
CHLM
03/11/19
UPGRADE
Target $13
CHLM
Buy
Ultra Clean upgraded to Buy on valuation at Craig-Hallum
Craig-Hallum analyst Christian Schwab upgraded Ultra Clean to Buy from Hold and established a $13 price target saying the selloff in shares following the Q4 report has created favorable risk/reward. Schwab said a WFE spending recovery remains cloudy, but his estimates are below Street expectations and shares look attractive based on his conservative expectations.
02/22/19
CHLM
02/22/19
DOWNGRADE
Target $13
CHLM
Hold
Ultra Clean downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum analyst Christian Schwab downgraded Ultra Clean Holdings to Hold from Buy and lowered his price target to $13 from $15 following the company's Q4 results. In a research note to investors, Schwab says with shares up about 50% year to date, he sees limited upside in the near-term until he has better visibility regarding a WFE spending recovery in 2020. Additionally, Schwab says he is also concerned regarding the lack of leverage in the model without a meaningful recovery in WFE given the additional OpEx and cost of debt associated with the Quantum Global acquisition.
03/21/19
COWN
03/21/19
NO CHANGE
Target $46
COWN
Outperform
Micron controller development unfavorable for Silicon Motion, says Cowen
Cowen analyst Karl Ackerman said Micron's (MU) guidance for the May quarter implies it is still annualizing more money in this downturn than it achieved in the prior peak cycle and that its "materially improved" NAND tech roadmap and expanding growth vectors in DRAM suggest that its free cash flow story is sustainable and underappreciated. However, he said he views Micron's capex read-through as negative for Ichor Holdings (ICHR) and Ultra Clean (UCTT) and he sees the company's controller development as unfavorable for Silicon Motion (SIMO). Ackerman raised his price target on Micron to $46 from $40 and keeps an Outperform rating on the shares.
OMCL Omnicell
$81.13

-0.03 (-0.04%)

04/26/19
BNCH
04/26/19
NO CHANGE
Target $90
BNCH
Buy
Omnicell price target raised to $90 from $82 at Benchmark
Benchmark analyst Bill Sutherland noted that Omnicell beat Q1 revenue expectations while "blowing away" adjusted EPS forecasts, stating that a sales force realignment is yielding larger and more sole-source deals. The analyst, who said he thinks the current revenue momentum can be at least sustained for the foreseeable future, raised his 2019 and 2020 adjusted EPS outlooks, increased his price target on Omnicell shares to $90 from $82 and keeps a Buy rating on the stock.
02/08/19
PIPR
02/08/19
NO CHANGE
Target $70
PIPR
Neutral
Omnicell price target raised to $70 from $59 at Piper Jaffray
Piper Jaffray analyst Sean Wieland raised his price target for Omnicell to $70 saying the company reported another strong quarter with record bookings and guided fiscal 2019 above expectations. Increasing product mix of platform and Software-as-a-Service-based deals take longer for overall backlog to convert to revenue, but provide visibility on future years, Wieland tells investors in a post-earnings research note. However, he believes 25 times earnings is the right valuation and reiterates a Neutral rating on Omnicell.
04/26/19
CHLM
04/26/19
DOWNGRADE
Target $84
CHLM
Hold
Omnicell downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum analyst Matt Hewitt downgraded Omnicell to Hold from Buy but raised his price target to $84 from $80 following the company's better than expected Q1 results on Thursday. Overall, Hewitt tells investors in a research note that he believes Omnicell is poised to continue growing the market and taking share for the foreseeable future, but with the stock trading at the highest level in over a decade from a valuation perspective, he believes much of this upside has been factored in. Therefore, he is stepping to the sidelines in the hopes of getting a better entry point.
04/26/19
CHLM
04/26/19
DOWNGRADE
CHLM
Hold
Omnicell downgraded to Hold from Buy at Craig-Hallum
STM STMicroelectronics
$15.10

-0.14 (-0.92%)

02/22/19
02/22/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Nvidia (NVDA) initiated with an Overweight at Atlantic Equities. 2. United Technologies (UTX) resumed with an Overweight at JPMorgan. 3. Wabtec (WAB) initiated with a Hold at Jefferies. 4. STMicroelectronics (STM) initiated with an Outperform at Cowen. 5. Biogen (BIIB) initiated with a Market Perform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/22/19
COWN
02/22/19
INITIATION
COWN
Outperform
STMicroelectronics initiated with an Outperform at Cowen
02/22/19
COWN
02/22/19
INITIATION
Target $21
COWN
Outperform
Cowen initiates STMicroelectonrics at Outperform, says turnaround complete
As reported previously, Cowen analyst Matthew Ramsay initiated STMicroelectronics with an Outperform rating as he believes the company has navigated a successful turnaround and positioned itself as a diversified analog and digital semiconductor supplier to the automotive and industrial markets. Ramsay, who believes the stock's current valuation does not reflect the company's opportunity, has a $21 price target on STMicroelectronics shares.
12/03/18
CHLM
12/03/18
NO CHANGE
CHLM
Auto suppliers should recover after U.S./China trade news, says Craig-Hallum
Craig-Hallum analyst Anthony Stoss expects auto supplier stocks to recover after positive meetings between President Trump and Chinese counterpart over the weekend. The analyst notes that 25% tariffs were pushed out 90 days to get final deal, and argues that automotive suppliers are too cheap and should work higher on the news. Stoss remains a buyer of STMicroelectronics (STM), ON Semiconductor (ON), and Cypress Semiconductor (CY) at current levels.
TTGT TechTarget
$20.24

0.38 (1.91%)

02/07/19
CHLM
02/07/19
NO CHANGE
Target $16
CHLM
Hold
TechTarget price target lowered to $16 from $23 at Craig-Hallum
Craig-Hallum analyst Mike Malouf lowered his price target for TechTarget to $16 from $23 as its legacy Core Online business of monetizing micro-specific websites that provide information to millions of domestic IT professionals continues to show weak results as large customers remain cautious around their marketing spend. While the analyst continues to see solid prospects for IT Deal Alert and expects that segment to be the primary secular growth driver in the coming years, the lackluster marketing spend environment is impacting that business as well. Malouf reiterates a Hold rating on the shares.
02/07/19
LSCM
02/07/19
NO CHANGE
Target $23
LSCM
Buy
TechTarget price target lowered to $23 from $26 at Lake Street
Lake Street analyst Eric Martinuzzi lowered his price target for TechTarget to $23 and reiterates a Buy rating on the shares following the company's Q4 results. Similar to last quarter, TechTarget says a few large customers are still finalizing budgets due to trade uncertainty, Martinuzzi tells investors in a research note. Further, while relatively small, there continues to be a negative overhang for a small number of large accounts around Europe's General Data Protection Regulation, adds the analyst. He points out TechTarget's fiscal 2019 growth is skewed towards the second half, which increases execution risk.
05/09/19
CHLM
05/09/19
UPGRADE
Target $26
CHLM
Buy
TechTarget upgraded to Buy from Hold at Craig-Hallum
Craig-Hallum analyst Mike Malouf upgraded TechTarget to Buy from Hold and raised his price target for the shares to $26 from $16. The analyst sees "heightened visibility of profitable growth" following last night's results. He believes TechTarget's Core Online business is seeing "solid" results.
05/09/19
LSCM
05/09/19
NO CHANGE
Target $24
LSCM
Buy
TechTarget target raised to $24 after Q1 upside at Lake Street
Lake Street analyst Eric Martinuzzi raised his price target for TechTarget to $24 from $23 citing the company's Q1 upside and increased 2019 EBITDA guidance. He keeps a Buy rating on the shares.
WTW Symbol now WW
$0.00

(0.00%)

03/12/19
JPMS
03/12/19
NO CHANGE
JPMS
Underweight
JPMorgan sees downside to WW revenue guidance and shares
JPMorgan analyst Christina Brathwaite continues to see risk to WW's 2019 revenue guidance, which she says "embeds trends improve significantly throughout the year." SimilarWeb data indicates that the company's daily active users in the U.S. remains weak with trends now down 39% year-over-year thus far quarter-to-date, which points to North America end of period subscribers down high-teens percent in Q1, Brathwaite tells investors in a research note. She points out that this is worse than the down low single-digit trend she's currently modeling. The analyst continues to see downside to WW shares and reiterates the stock as her top Focus List short idea. Brathwaite has an Underweight rating on the name with a $14 price target.
04/11/19
JPMS
04/11/19
NO CHANGE
Target $12
JPMS
Underweight
WW price target lowered to $12 from $14 at JPMorgan
JPMorgan analyst Christina Brathwaite lowered her estimates on WW saying daily active user data in the U.S. has tracked even worse than her bearish expectations. Daily active users dropped 40% year-over-year during Q1, according to SimilarWeb, Brathwaite tells investors in a research note. By the analyst's math, the data imply WW's North America subscribers are around 2.5M, or down 18% year-over-year, which she says would put "significant pressure" on the company's revenue for the year. The analyst lowered her price target for WW to $12 from $14 and maintains an Underweight rating on the shares. She reiterates the company as her top short pick.
04/15/19
MSCO
04/15/19
NO CHANGE
Target $21
MSCO
Equal Weight
WW tracker points to subscriber stabilization in Q1, says Morgan Stanley
Morgan Stanley analyst Vincent Sinisi said his "MAD" tracker that uses WW app downloads points to Q1 end subscribers of about 4.5M, which he notes is relatively in-line with guidance from the company for its subscriber count to be "down slightly." The company's app download trends sequentially improved through the quarter ending in March, which Sinisi said he views as a "constructive sign." While he keeps an Equal Weight rating on WW shares, the analyst said he sees "tactical upside at these levels" into the company's next report in May.
02/27/19
02/27/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Home Depot (HD) downgraded to Hold from Buy at DZ Bank and to Market Perform from Outperform at Telsey Advisory. 2. Chubb (CB) downgraded to Underperform from Neutral at Credit Suisse with analyst Michael Zaremski saying he thinks the assumed catastrophe load embedded within consensus EPS forecasts is materially too low/optimistic, and as he has less confidence that the company will be able to organically grow policy counts in its peer-leading US high-net-worth personal home/auto businesses due to heightened competition from new entrants, one of whom is led by a spate of former Chubb executives. The analyst also lowered his price target on the shares to $131 from $141. 3. Heska (HSKA) downgraded to Hold from Buy at Benchmark wth analyst Bruce Jackson saying he reduced his estimates following the company's Q4 miss and "disappointing" 2019 guidance. 4. WW (WTW) downgraded to Neutral from Buy at DA Davidson, to Hold from Buy at SunTrust and Craig-Hallum, to Sector Weight from Overweight at KeyBanc, and to Perform from Outperform at Oppenheimer. 5. Unilever (UN, UL) downgraded to Neutral from Outperform at Exane BNP Paribas. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

VTR

Ventas

$69.65

1.05 (1.53%)

21:28
06/19/19
06/19
21:28
06/19/19
21:28
Upgrade
Ventas rating change at Stifel »

Stifel upgrades to Ventas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$197.87

-0.65 (-0.33%)

21:22
06/19/19
06/19
21:22
06/19/19
21:22
Initiation
Apple initiated at Deutsche Bank »

Apple initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

DELL

Dell Technologies

$53.39

1.88 (3.65%)

21:22
06/19/19
06/19
21:22
06/19/19
21:22
Initiation
Dell Technologies initiated at Deutsche Bank »

Dell Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

HPQ

HP Inc.

$20.63

0.1 (0.49%)

21:21
06/19/19
06/19
21:21
06/19/19
21:21
Initiation
HP Inc. initiated at Deutsche Bank »

HP Inc. initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 01

    Jul

  • 02

    Jul

  • 03

    Jul

  • 04

    Jul

GNCA

Genocea

$3.84

-1.32 (-25.58%)

21:18
06/19/19
06/19
21:18
06/19/19
21:18
Syndicate
Genocea 10M share Secondary priced at $3.50 »

SVB Leerink and Stifel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

PSNL

Personalis

$0.00

(0.00%)

21:15
06/19/19
06/19
21:15
06/19/19
21:15
Syndicate
Personalis 7.922M share IPO priced at $17.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

CYRX

Cryoport

$18.62

-0.08 (-0.43%)

21:13
06/19/19
06/19
21:13
06/19/19
21:13
Syndicate
Cryoport 3.75M share Spot Secondary priced at $17.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

VTR

Ventas

$69.65

1.05 (1.53%)

20:41
06/19/19
06/19
20:41
06/19/19
20:41
Upgrade
Ventas rating change at Stifel »

Ventas upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSY

Hershey

$137.94

-0.29 (-0.21%)

20:27
06/19/19
06/19
20:27
06/19/19
20:27
Downgrade
Hershey rating change at Piper Jaffray »

Hershey downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KR

Kroger

$23.64

-0.3 (-1.25%)

, DRI

Darden

$117.55

-0.39 (-0.33%)

20:25
06/19/19
06/19
20:25
06/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KR

Kroger

$23.64

-0.3 (-1.25%)

DRI

Darden

$117.55

-0.39 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 20

    Jun

  • 25

    Jun

  • 27

    Jun

DAL

Delta Air Lines

$56.38

0.33 (0.59%)

20:08
06/19/19
06/19
20:08
06/19/19
20:08
Periodicals
Breaking Periodicals news story on Delta Air Lines »

Delta working on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

SPY

SPDR S&P 500 ETF Trust

$293.02

0.69 (0.24%)

, SPX

S&P 500

$0.00

(0.00%)

20:00
06/19/19
06/19
20:00
06/19/19
20:00
Periodicals
Breaking Periodicals news story on SPDR S&P 500 ETF Trust, S&P 500 »

Trump not planning to…

SPY

SPDR S&P 500 ETF Trust

$293.02

0.69 (0.24%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARZGY

Generali

$0.00

(0.00%)

19:22
06/19/19
06/19
19:22
06/19/19
19:22
Downgrade
Generali rating change at JPMorgan »

Generali downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GO

Grocery Outlet

$0.00

(0.00%)

19:00
06/19/19
06/19
19:00
06/19/19
19:00
Syndicate
Grocery Outlet 17.19M share IPO priced at $22.00 »

The deal priced above the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

WIX

Wix.com

$145.83

1.19 (0.82%)

18:57
06/19/19
06/19
18:57
06/19/19
18:57
Hot Stocks
Wix.com CEO: Q1 was very good for us »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AOBC

American Outdoor Brands

$9.17

0.13 (1.44%)

, ORCL

Oracle

$52.69

-0.19 (-0.36%)

18:44
06/19/19
06/19
18:44
06/19/19
18:44
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

AOBC

American Outdoor Brands

$9.17

0.13 (1.44%)

ORCL

Oracle

$52.69

-0.19 (-0.36%)

JSYN

Jensyn Acquisition

$5.00

-5.02 (-50.10%)

ABEO

Abeona Therapeutics

$4.90

-0.09 (-1.80%)

PIR

Pier 1 Imports

$0.67

-0.0059 (-0.87%)

SCS

Steelcase

$17.80

0.235 (1.34%)

LAND

Gladstone Land

$12.29

0.39 (3.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 19

    Jun

  • 20

    Jun

  • 24

    Jun

  • 26

    Jun

  • 26

    Jun

  • 10

    Jul

  • 20

    Jun

TMUS

T-Mobile

$78.28

1.79 (2.34%)

, S

Sprint

$7.46

0.24 (3.32%)

18:39
06/19/19
06/19
18:39
06/19/19
18:39
Periodicals
T-Mobile readies for Boost auction if Dish talks fall through, Reuters says »

T-Mobile (TMUS) is…

TMUS

T-Mobile

$78.28

1.79 (2.34%)

S

Sprint

$7.46

0.24 (3.32%)

DISH

Dish

$38.90

-0.18 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBRA

Zebra Technologies

$200.57

-1.1 (-0.55%)

18:39
06/19/19
06/19
18:39
06/19/19
18:39
Hot Stocks
Zebra Technologies Chief of Product sells 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBRA

Zebra Technologies

$200.57

-1.1 (-0.55%)

18:23
06/19/19
06/19
18:23
06/19/19
18:23
Hot Stocks
Zebra Technologies CEO sells 20K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$250.25

4.6 (1.87%)

, DVA

DaVita

$51.27

1.51 (3.03%)

18:13
06/19/19
06/19
18:13
06/19/19
18:13
Hot Stocks
FTC approves UnitedHealth's acquisition of DaVita Medical with conditions »

Healthcare provider and…

UNH

UnitedHealth

$250.25

4.6 (1.87%)

DVA

DaVita

$51.27

1.51 (3.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

SRRK

Scholar Rock

$17.11

-2.835 (-14.21%)

18:11
06/19/19
06/19
18:11
06/19/19
18:11
Syndicate
Scholar Rock 3M share Secondary priced at $15.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

QDEL

Quidel

$58.80

1.7 (2.98%)

18:01
06/19/19
06/19
18:01
06/19/19
18:01
Hot Stocks
Quidel receives 510k clearance for Triage TOX Drug Screen »

Quidel Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DELL

Dell Technologies

$53.39

1.88 (3.65%)

, HPQ

HP Inc.

$20.63

0.1 (0.49%)

17:59
06/19/19
06/19
17:59
06/19/19
17:59
Periodicals
Dell, HP, Intel, Microsoft express opposition to Trump tariffs, Bloomberg says »

Dell Technologies (DELL),…

DELL

Dell Technologies

$53.39

1.88 (3.65%)

HPQ

HP Inc.

$20.63

0.1 (0.49%)

INTC

Intel

$47.08

-0.29 (-0.61%)

MSFT

Microsoft

$135.63

0.43 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 23

    Jun

  • 28

    Jun

  • 01

    Jul

  • 02

    Jul

  • 03

    Jul

  • 04

    Jul

  • 09

    Jul

  • 09

    Jul

  • 10

    Jul

  • 25

    Jul

  • 06

    Aug

ORCL

Oracle

$52.69

-0.19 (-0.36%)

17:54
06/19/19
06/19
17:54
06/19/19
17:54
Hot Stocks
Oracle says 20% of Autonomous Database customers new to company »

Says plans to launch free…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

CB

Chubb

$149.48

1.37 (0.92%)

17:54
06/19/19
06/19
17:54
06/19/19
17:54
Hot Stocks
Chubb CEO sells 215.6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.